^
Association details:
| Biomarker: | MYD88 L265P + CXCR4 mutation |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia
Published date:
11/01/2018
Excerpt:
We therefore initiated a phase II study to evaluate the safety and efficacy of venetoclax monotherapy in previously treated patients with WM (NCT02677324)....All patients carried the MYD88L265P mutation, and 16 (53%) also had a CXCR4 mutation….VGPR rates were lower in those with prior BTK-i exposure (7% vs. 27%; p=0.10), and CXCR4 mutations (6% vs. 29%; p=0.10).
DOI:
10.1182/blood-2018-99-112325
Trial ID:
